Monograph Details
|
|
Infections & Infestations
> Fungal infections
|
|
ERAXIS |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Glucan synthesis inhibitor (echinocandin). |
| Generic Name |
|
Anidulafungin 50mg/vial; pwd for IV infusion after reconstitution and dilution; preservative-free; contains fructose and mannitol. |
| Indications |
|
Candidemia. Esophageal candidiasis. Other Candida infections (intra-abominal abscess, peritonitis). |
| Children |
|
Not recommended. |
| Adults |
|
Give by IV infusion; max rate 1.1mg/minute. Candidiasis, intra-abdominal abscess, peritonitis: 200mg on day 1, then 100mg/day for at least 14 days after last positive culture. Esophageal candidiasis: 100mg on day 1, then 50mg/day for at least 14 days and at least 7 days after symptom resolution. |
| Precautions |
|
Follow-up if hepatic dysfunction develops. Pregnancy (Cat.C). Nursing mothers. |
| Adverse Reactions |
|
Infusion reactions. |
| How Supplied |
|
Vial (w. diluent)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
